Ligand Pharmaceuticals (NASDAQ:LGND) Updates FY 2025 Earnings Guidance

Ligand Pharmaceuticals (NASDAQ:LGND - Get Free Report) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share guidance of 6.000-6.250 for the period, compared to the consensus earnings per share estimate of 6.140. The company issued revenue guidance of $180.0 million-$200.0 million, compared to the consensus revenue estimate of $188.8 million.

Analysts Set New Price Targets

Several research analysts have recently issued reports on LGND shares. HC Wainwright restated a "buy" rating on shares of Ligand Pharmaceuticals in a report on Wednesday, December 11th. Benchmark restated a "buy" rating and set a $135.00 price target on shares of Ligand Pharmaceuticals in a research note on Monday, December 23rd. Oppenheimer raised their price objective on Ligand Pharmaceuticals from $135.00 to $147.00 and gave the stock an "outperform" rating in a research report on Friday, November 8th. Royal Bank of Canada lifted their price objective on Ligand Pharmaceuticals from $141.00 to $143.00 and gave the stock an "outperform" rating in a report on Wednesday, December 11th. Finally, Barclays upped their target price on Ligand Pharmaceuticals from $150.00 to $160.00 and gave the company an "overweight" rating in a research note on Monday, December 16th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $147.00.

Ligand Pharmaceuticals Stock Performance

Shares of NASDAQ LGND traded down $10.05 during midday trading on Monday, reaching $112.18. 164,244 shares of the company traded hands, compared to its average volume of 94,479. Ligand Pharmaceuticals has a 12 month low of $67.72 and a 12 month high of $129.90. The stock's 50-day simple moving average is $114.18 and its 200-day simple moving average is $111.29. The firm has a market cap of $2.12 billion, a PE ratio of 44.69 and a beta of 1.04.

Remove Ads

Insider Activity at Ligand Pharmaceuticals

In related news, CFO Octavio Espinoza sold 2,104 shares of the firm's stock in a transaction on Monday, December 23rd. The stock was sold at an average price of $116.37, for a total transaction of $244,842.48. Following the completion of the sale, the chief financial officer now directly owns 20,647 shares of the company's stock, valued at $2,402,691.39. This trade represents a 9.25 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 5.90% of the stock is currently owned by insiders.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.